Atea/$AVIR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Atea

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Ticker

$AVIR
Sector
Primary listing

Employees

55

Atea Metrics

BasicAdvanced
$433m
-
-$1.94
0.26
-

What the Analysts think about Atea

Analyst ratings (Buy, Hold, Sell) for Atea stock.

Atea Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37bn
-39.75%
Net income
$45bn
107.52%
Profit margin
37.65%
6.78%

Atea Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AVIR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs